文献速递免疫规划传染病防控与疫情报告

评估WRSs2和WRSs3两种宋内志贺菌活口服候选疫苗安全性和免疫原性的I期试验

A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.
PubMed 文献 · Vaccine · 2018-07-02

本研究将18-45岁健康成人分配至5个队列(每队18人,WRSs2组8人、WRSs3组8人、安慰剂组2人),单次口服递增剂量(10^3 CFU至10^7 CFU)的WRSs2或WRSs3疫苗。两种疫苗在整个剂量范围内总体耐受良好且安全,80名受种者中11人出现腹泻(8人为轻度),并产生剂量依赖性黏膜和全身免疫应答,似乎与粪便排菌相关。

要点

  • WRSs2和WRSs3在10^3至10^7 CFU剂量范围内总体耐受良好且安全。
  • 80名受种者中11人出现腹泻,其中8人为轻度且不影响日常活动。
  • 受种者产生剂量依赖性黏膜和全身免疫应答,似乎与粪便排菌相关。

核心结论

  • 宋内志贺菌候选疫苗WRSs2和WRSs3在宽剂量范围内安全且具有免疫原性。

研究设计与样本

  • I期试验将18-45岁健康成人分配至5个队列,每队18人(WRSs2组8人、WRSs3组8人、安慰剂组2人)。
  • 受试者住院并单次口服研究药物,剂量递增(10^3 CFU至10^7 CFU),于口服碳酸氢钠5分钟后给药。

主要发现

  • 80名受种者中11人出现腹泻,其中8人为轻度且不影响日常活动。
  • 在10^7 CFU剂量下,WRSs2组1人发生中度腹泻,而WRSs3组2人发生中度或重度腹泻。
  • 受种者产生剂量依赖性黏膜和全身免疫应答,似乎与粪便排菌相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Effective vaccines are needed to combat diarrheal diseases due to Shigella. Two live oral S. sonnei vaccine candidates, WRSs2 and WRSs3, attenuated principally by the lack of spreading ability, as well as the loss of enterotoxin and acyl transferase genes, were tested for safety and immunogenicity. Healthy adults 18-45 years of age, assigned to 5 cohorts of 18 subjects each (WRSs2 (n = 8), WRSs3 (n = 8) or placebo (n = 2)) were housed in an inpatient facility and administered a single oral dose of study agent 5 min after ingestion of oral bicarbonate. Ascending dosages of vaccine (from 103 CFU to 107 CFU) were evaluated. On day 8, treatment with ciprofloxacin (500 mg BID for 3 days) was initiated and subjects were discharged home 2 days after completing antibiotics. Subjects returned for outpatient visits on day 14, 28 and 56 post-vaccination for monitoring and collection of stool and blood samples. Both WRSs2 and WRSs3 were generally well tolerated and safe over the entire dose range. Among the 80 vaccinees, 11 subjects developed diarrhea, 8 of which were mild and did not affect daily activities. At the 107 CFU dose, moderate diarrhea occurred in one WRSs2 subject while at the same dose of WRSs3, 2 subjects had moderate or severe diarrhea. Vaccinees mounted dose-dependent mucosal and systemic immune responses that appeared to correlate with fecal shedding. S. sonnei vaccine candidates WRSs2 and WRSs3 are safe and immunogenic over a wide dose range. Future steps will be to select the most promising candidate and move to human challenge models for efficacy of the vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Frenck RW, Baqar S, Alexander W, et al. A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei. Vaccine. 2018. PMID: 30037478. doi:10.1016/j.vaccine.2018.06.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。